GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Cyclically Adjusted PS Ratio

Core One Labs (XCNQ:COOL) Cyclically Adjusted PS Ratio : 0.13 (As of May. 15, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Core One Labs's current share price is C$0.195. Core One Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was C$1.55. Core One Labs's Cyclically Adjusted PS Ratio for today is 0.13.

The historical rank and industry rank for Core One Labs's Cyclically Adjusted PS Ratio or its related term are showing as below:

XCNQ:COOL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.12   Med: 0.27   Max: 0.94
Current: 0.14

During the past years, Core One Labs's highest Cyclically Adjusted PS Ratio was 0.94. The lowest was 0.12. And the median was 0.27.

XCNQ:COOL's Cyclically Adjusted PS Ratio is ranked better than
96.49% of 513 companies
in the Biotechnology industry
Industry Median: 5.58 vs XCNQ:COOL: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Core One Labs's adjusted revenue per share data for the three months ended in Dec. 2023 was C$0.002. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$1.55 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Core One Labs Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Core One Labs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Cyclically Adjusted PS Ratio Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.37

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.37 0.41 0.25 0.19

Competitive Comparison of Core One Labs's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Core One Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Core One Labs's Cyclically Adjusted PS Ratio falls into.



Core One Labs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Core One Labs's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.195/1.55
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Core One Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Core One Labs's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.002/125.4675*125.4675
=0.002

Current CPI (Dec. 2023) = 125.4675.

Core One Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.000 97.419 0.000
201312 0.000 96.945 0.000
201403 0.000 98.604 0.000
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.263 100.500 0.328
201509 0.232 100.421 0.290
201512 -0.063 99.947 -0.079
201603 0.033 101.054 0.041
201606 0.050 102.002 0.062
201609 0.000 101.765 0.000
201612 0.076 101.449 0.094
201703 0.358 102.634 0.438
201706 1.047 103.029 1.275
201709 0.000 103.345 0.000
201712 -0.685 103.345 -0.832
201803 0.000 105.004 0.000
201806 0.288 105.557 0.342
201809 0.527 105.636 0.626
201812 2.535 105.399 3.018
201903 4.351 106.979 5.103
201906 0.776 107.690 0.904
201909 0.416 107.611 0.485
201912 -2.800 107.769 -3.260
202003 0.000 107.927 0.000
202006 0.000 108.401 0.000
202009 0.000 108.164 0.000
202012 0.000 108.559 0.000
202103 0.000 110.298 0.000
202106 0.000 111.720 0.000
202109 0.000 112.905 0.000
202112 0.027 113.774 0.030
202203 0.005 117.646 0.005
202206 0.005 120.806 0.005
202209 0.004 120.648 0.004
202212 0.007 120.964 0.007
202309 0.002 125.230 0.002
202312 0.002 125.468 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Core One Labs  (XCNQ:COOL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Core One Labs Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Core One Labs's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.
Executives
Joel Shacker Director, Senior Officer